559 related articles for article (PubMed ID: 37328642)
1. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy.
Yang K; Halima A; Chan TA
Nat Rev Clin Oncol; 2023 Sep; 20(9):604-623. PubMed ID: 37328642
[TBL] [Abstract][Full Text] [Related]
2. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.
Maggs L; Sadagopan A; Moghaddam AS; Ferrone S
Trends Cancer; 2021 Dec; 7(12):1089-1101. PubMed ID: 34489208
[TBL] [Abstract][Full Text] [Related]
3. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
Seliger B; Ferrone S
Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
[TBL] [Abstract][Full Text] [Related]
4. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.
Sabbatino F; Schwab JH; Ferrone S; Ferrone CR
Clin Transpl; 2013; ():453-63. PubMed ID: 25095541
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.
Sadagopan A; Michelakos T; Boyiadzis G; Ferrone C; Ferrone S
JAMA Oncol; 2022 Mar; 8(3):462-473. PubMed ID: 34940799
[TBL] [Abstract][Full Text] [Related]
7. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
Sabbatino F; Liguori L; Polcaro G; Salvato I; Caramori G; Salzano FA; Casolaro V; Stellato C; Col JD; Pepe S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023239
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
9. Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response.
Chen R; Zhang H; Wu W; Li S; Wang Z; Dai Z; Liu Z; Zhang J; Luo P; Xia Z; Cheng Q
Front Immunol; 2022; 13():833792. PubMed ID: 35418980
[TBL] [Abstract][Full Text] [Related]
10. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.
Wang S; He Z; Wang X; Li H; Liu XS
Elife; 2019 Nov; 8():. PubMed ID: 31767055
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Wang S; Xie K; Liu T
Front Immunol; 2021; 12():690112. PubMed ID: 34367148
[TBL] [Abstract][Full Text] [Related]
12. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
13. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
14. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy.
D'Amico S; Tempora P; Melaiu O; Lucarini V; Cifaldi L; Locatelli F; Fruci D
Front Immunol; 2022; 13():948297. PubMed ID: 35936007
[TBL] [Abstract][Full Text] [Related]
15. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
17. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.
Concha-Benavente F; Srivastava R; Ferrone S; Ferris RL
Oral Oncol; 2016 Jul; 58():52-8. PubMed ID: 27264839
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
19. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
Gray SG
BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
[TBL] [Abstract][Full Text] [Related]
20. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
